Geisinger enrolls first patient in amyloid cardiomyopathy trial
DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.
- DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.
- "If a patient qualifies for the clinical trial, it will allow us to provide a treatment option when they receive an amyloidosis diagnosis without having to travel outside of the region for care," said Dr.
- "Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life."
- The trial is a phase 3, randomized, double-blind, placebo-controlled study that evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).